BRNS vs CABA

Barinthus Biotherapeutics plc vs Cabaletta Bio, Inc. — Valuation Comparison 2026

BRNS

Biotechnology
Barinthus Biotherapeutics plc
Quality
6.0
out of 10
Value Trap
24
SAFE
Price
$0.68
Last close
Models
9/13
Active
VS

CABA

Biotechnology
Cabaletta Bio, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$3.77
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BRNS Fair ValueBRNS Upside CABA Fair ValueCABA Upside
Bayesian DCF Intrinsic $0.94 +37.8% $1.10 -70.8%
First Chicago Scenario $0.26 -63.5% $5.09 +44.0%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.83 +167.5% $1.45 -61.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BRNS vs CABA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BRNS vs CABA — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs CABA's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Barinthus Biotherapeutics plc (BRNS) and Cabaletta Bio, Inc. (CABA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BRNS currently trades at $0.68 with a QOC of 6.0/10, while CABA trades at $3.77 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).